התגלית נולדה כאן - המפעל יקום בחו"ל

הערכה

Israeli medical innovation consistently generates breakthroughs, but the commercial production and economic benefits migrate abroad. The pattern costs Israel far more than most realize, though the precise figure rarely gets calculated publicly. What matters now is whether this dynamic represents a structural failure or a rational division of labor in a globalized industry. Watch for whether government incentives or regulatory reforms attempt to shift this balance, or whether the system accepts the loss as the price of staying competitive.